Key Highlights

● Pomdoctor traded at about $1.84 on October 22, an intraday figure.

● The decline more than erased Wednesday's spike.

● Pomdoctor has a market value of roughly $1.8 million.

● The Russell 2000 edged up 3.01 points to 2,784.03.

Shares of Pomdoctor (NASDAQ:POM) plunged on Thursday, October 22, 2026, trading at about $1.84 during the session and ranking among the steepest decliners on the Nasdaq Composite. The stock had also been sharply lower in premarket trading.

The fall reversed a spike on Wednesday, when the shares soared. Thursday's decline more than erased that gain.

Neither move came with a company-specific announcement. Pomdoctor did not issue a press release, results or a regulatory filing tied to Thursday's drop.

A very small company

Pomdoctor has a market value of roughly $1.8 million, making it a tiny company by market standards. It is grouped among health care stocks.

Stocks of this size can be highly volatile on thin news. With few shares trading and a low share price, a modest number of orders can move the price sharply in either direction, and big gains can unwind as quickly as they appear.

The pattern on display, a surge one day followed by a slump the next, is common among micro caps. Traders who buy on a spike may rush to take profits, while others who missed the first move may stay away, leaving few buyers to absorb the selling.

A rough day across the index

Pomdoctor's slide came on a difficult day for the Nasdaq. The Composite closed at 26,008.86, down 694.00 points, its steepest drop since June 5. The decline ended a seven-session winning streak and erased about $1 trillion in market value, according to market data.

The heaviest selling was in AI and semiconductor stocks. The heavy spending plans from Meta Platforms (NASDAQ:META), released after Wednesday's close, and Lam Research (NASDAQ:LRCX)'s supply-constrained outlook revived concerns over the cost of building AI infrastructure. The Philadelphia Semiconductor Index posted its biggest one-day drop since June 23.

Breadth on the Nasdaq was negative, with 2,766 decliners against 2,022 advancers and 342 new lows against 82 new highs, according to market data.

Health care: strong at the top, mixed at the bottom

The health care sector as a whole did well. The S&P 500 health care sector hit a record high, according to market data, as investors rotated out of technology and into defensive areas. Consumer staples had their best day since April 2025.

The gains were concentrated in larger, established companies. Among smaller health care stocks, the picture was far more mixed. Several micro-cap names posted big moves in both directions with no news, while Moderna (NASDAQ:MRNA) tumbled after Phase 3 melanoma vaccine data that it is developing with Merck (NYSE:MRK) appeared before its scheduled presentation.

The Russell 2000, a benchmark for smaller US companies, edged up 3.01 points to 2,784.03, a sign that the day's turbulence in tiny stocks was not a broad small-cap selloff.

Reading the numbers

The $1.84 price was an intraday snapshot, not a confirmed closing level. In stocks this small, prices can vary considerably over the course of a session, and premarket and intraday figures from different data providers can differ.

The stock's swing was also far larger than anything seen in the broad indexes, where the Dow Jones Industrial Average finished essentially flat.

Pomdoctor Faces Continued Volatility

Investors will look for any announcement or filing from Pomdoctor that might explain the recent swings, and for whether the volatility continues on Friday. In health care, full data from the Moderna and Merck melanoma trial are due Saturday at the ESMO meeting. Market-wide, the Federal Reserve announces its decision on Wednesday, October 28.